Palatin Technologies, Inc.
PTN
NASDAQ·Healthcare·Biotechnology·Mkt cap $22.6M
$12.70
▼ -2.91%
P/E
2.64
Mkt Cap
$22.6M
52-Wk Range
$5.61–$31.00
52-Week Range
$5.61 - $31.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 46.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta -0.1).
Growth
Profitability at risk
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-10.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PTN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
Most recent quarter reported revenue of $8.8M. Reported EPS of $4.81.
Reported EPS · last 4Q
Q1 26
$4.81
Revenue trend · last 1Q
—
Q1 26
$8.8M
Margins · last 1Q
Profit
52.9%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How PTN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.